Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175248
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gómez, Carmen Elena | - |
dc.contributor.author | Perdiguero, Beatriz | - |
dc.contributor.author | García Arriaza, Juan | - |
dc.contributor.author | Cepeda, Victoria | - |
dc.contributor.author | Sánchez Sorzano, Carlos Oscar | - |
dc.contributor.author | Mothe, Beatriz | - |
dc.contributor.author | Jiménez, José Luis | - |
dc.contributor.author | Muñoz Fernández, María Ángeles | - |
dc.contributor.author | Gatell, José M | - |
dc.contributor.author | López Bernaldo de Quirós, Juan Carlos | - |
dc.contributor.author | Brander, Christian | - |
dc.contributor.author | García Alcaide, Felipe | - |
dc.contributor.author | Esteban, Mariano | - |
dc.date.accessioned | 2021-03-17T12:38:07Z | - |
dc.date.available | 2021-03-17T12:38:07Z | - |
dc.date.issued | 2015-11-06 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175248 | - |
dc.description.abstract | Trial Design: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. Conclusion: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0141456 | - |
dc.relation.ispartof | PLoS One, 2015, vol. 10, num. 11, p. e0141456 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0141456 | - |
dc.rights | cc-by (c) Gómez, Carmen Elena et al., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Vacunes antivíriques | - |
dc.subject.classification | Cèl·lules T | - |
dc.subject.other | HIV (Viruses) | - |
dc.subject.other | Viral vaccines | - |
dc.subject.other | T cells | - |
dc.title | A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 693527 | - |
dc.date.updated | 2021-03-17T12:38:07Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 26544853 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
693527.pdf | 1.47 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License